食品与发酵工业 >

2026 , Vol. 52 >Issue 12: 335 - 344

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.044487

研究报告

短双歧杆菌CCFM1489联合决明子苷缓解代谢相关脂肪性肝病的效果与机制研究

  • 殷梦琪 ,
  • 朱颖炜 ,
  • 崔树茂 ,
  • 唐鑫
展开
  • 1(江南大学 无锡医学院,江苏 无锡,214122)
    2(江南大学附属中心医院,江苏 无锡,214002)
    3(江南大学 食品学院,江苏 无锡,214122)
第一作者:硕士研究生(朱颖炜主任医师为通信作者,E-mail:zhuyingw2020@163.com)

收稿日期: 2025-09-15

  修回日期: 2025-10-29

  网络出版日期: 2026-07-17

基金资助

无锡市卫生健康委科研重大项目(Z202415);无锡市科技局“太湖之光”科技研究项目(2023186)

收起

Combined efficacy and mechanisms of Bifidobacterium breve CCFM1489 and Cassiaside in alleviating metabolic dysfunction-associated fatty liver disease

  • YIN Mengqi ,
  • ZHU Yingwei ,
  • CUI Shumao ,
  • TANG Xin
Expand
  • 1(Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China)
    2(Jiangnan University Medical Center, Wuxi 214002, China)
    3(School of Food Science and Technology, Jiangnan University, Wuxi 214122, China)

Received date: 2025-09-15

  Revised date: 2025-10-29

  Online published: 2026-07-17

Fold

摘要

该研究探讨了短双歧杆菌CCFM1489联合决明子苷缓解代谢相关脂肪性肝病(metabolic dysfunction-associated fatty liver disease, MAFLD)的效果与机制。选取5周龄雄性C57BL/6 J小鼠,随机分为空白组、模型组、阿托伐他汀组、决明子苷组、活菌组、合生制剂组、后生元组,高脂饮食饲养8周构建小鼠MAFLD模型。灌胃给药4周后评估各组肥胖特征、血糖代谢能力、血脂、机体炎症、肝脏损伤及肝脏病理学,并结合16S rRNA肠道菌群测序与非靶向代谢组学揭示短双歧杆菌CCFM1489联合决明子苷缓解MAFLD的作用机制。结果表明,与模型组相比,后生元可显著降低MAFLD小鼠的体重、肝重比、口服葡萄糖耐受(oral glucose tolerance test, OGTT)血糖曲线下面积、总胆固醇(total cholesterol, TC)、甘油三酯(triglyceride, TG)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol, LDL-C)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol, HDL-C)、谷丙转氨酶(alanine aminotransferase, ALT)、谷草转氨酶(aspartate aminotransferase, AST)水平,减轻机体炎症反应,并显著改善肝脏病理形态并降低肝脏中脂肪积累。肠道菌群分析表明,后生元干预能够在门水平提高拟杆菌门丰度以及降低厚壁菌门丰度,并在属水平上特异性降低Erysipelatoclostridium、Ruminococcaceae UCG-004属丰度。代谢组学分析表明,后生元可能通过调节乙醛酸和二羧酸代谢、牛磺酸和次牛磺酸代谢、谷胱甘肽代谢通路从而发挥缓解MAFLD的效果。短双歧杆菌CCFM1489-决明子苷后生元通过调节肠道菌群结构并调控乙醛酸/二羧酸代谢、牛磺酸代谢及谷胱甘肽代谢网络缓解MAFLD病理进程,为MAFLD微生态干预策略提供了新思路。

关键词： 决明子苷; 短双歧杆菌CCFM1489; 后生元; 代谢相关性脂肪肝; 肠道菌群; 代谢组

本文引用格式

殷梦琪 , 朱颖炜 , 崔树茂 , 唐鑫 . 短双歧杆菌CCFM1489联合决明子苷缓解代谢相关脂肪性肝病的效果与机制研究[J]. 食品与发酵工业, 2026 , 52(12) : 335 -344 . DOI: 10.13995/j.cnki.11-1802/ts.044487

Abstract

Investigating the effects and mechanisms of Bifidobacterium breve CCFM1489 combined with Cassiaside in alleviating metabolic dysfunction-associated fatty liver disease(MAFLD).Five-week-old male C57BL/6 J mice were selected and randomly divided into control group, model group, atorvastatin group, Cassiaside group, CCFM1489 group, synbiotic group, and postbiotic group, and were fed with high-fat diet for 8 weeks to establish a MAFLD model.Following 4-week intragastric drug administration, this study assessed the obesity characteristics, glucose metabolism capacity, blood lipids, body inflammation, liver injury, and liver pathology of each group, combining with the 16S rRNA intestinal flora sequencing and untargeted metabolomics to reveal the mechanism of action of Bifidobacterium breve CCFM1489 in combination with Cassiaside to alleviate MAFLD.Compared with the model group, postbiotics significantly reduced body weight, liver weight ratio, area under the oral glucose tolerance test (OGTT) glucose curve, TC, TG, LDL-C, HDL-C, ALT, AST, and body inflammation in MAFLD mice.Hematoxylin-eosin staining and oil red O staining showed that the postbiotic group was able to significantly improve liver pathomorphology and reduce fat accumulation in the liver.Intestinal flora analysis showed that the intervention of postbiotic was able to increase the abundance of Bacteroidetes and decrease the abundance of Firmicutes at the phylum level, and specifically decrease the abundance of Erysipelatoclostridium, Ruminococcaceae UCG-004 at the genus level.Metabolomics analyses suggested that postbiotics may exert a mitigating effect on MAFLD by modulating glyoxylate and dicarboxylic acid metabolism, taurine and hypotaurine metabolism, and glutathione metabolism.Bifidobacterium breve CCFM1489-Cassiaside postbiotics alleviated the pathological process of MAFLD by regulating the intestinal flora structure and modulating the glyoxylate/dicarboxylic acid metabolism, taurine metabolism and glutathione metabolism, providing a new idea for the microecological intervention strategy of MAFLD.

Key words： Cassiaside; Bifidobacterium breve CCFM1489; postbiotics; metabolic dysfunction-associated fatty liver disease; intestinal flora; metabolomics

参考文献

[1] LE M H, LE D M, BAEZ T C, et al.Global incidence of non-alcoholic fatty liver disease:A systematic review and meta-analysis of 63 studies and 1,201,807 persons[J].Journal of Hepatology, 2023, 79(2):287-295.
[2] KAYA E, YILMAZ Y.Metabolic-associated fatty liver disease (MAFLD):A multi-systemic disease beyond the liver[J].Journal of Clinical and Translational Hepatology, 2022, 10(2):329-338.
[3] RONG L, ZOU J Y, RAN W, et al.Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)[J].Frontiers in Endocrinology, 2023, 13:1087260.
[4] EASL, EASD, EASO.Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J].Journal of Hepatology, 2024, 81(3):492-542.
[5] 葛肖波, 薛晓琳, 李鑫, 等.基于现代文献探讨干预血脂异常的药食同源类药物用药特点及其病机分析[J].世界中西医结合杂志, 2020, 15(5):845-849.
GE X B, XUE X L, LI X, et al.Analysis of medication law of edible and medicinal Chinese herbs and pathogenesis that interfere with dyslipidemia based on literature[J].World Journal of Integrated Traditional and Western Medicine, 2020, 15(5):845-849.
[6] TZENG T F, LU H J, LIOU S S, et al.Cassia tora (Leguminosae) seed extract alleviates high-fat diet-induced nonalcoholic fatty liver[J].Food and Chemical Toxicology, 2013, 51:194-201.
[7] GUO C Y, LIAO W T, QIU R J, et al.Aurantio-obtusin improves obesity and insulin resistance induced by high-fat diet in obese mice[J].Phytotherapy Research, 2021, 35(1):346-360.
[8] JUNG D H, KIM Y S, KIM N H, et al.Extract of Cassiae Semen and its major compound inhibit S100b-induced TGF-β and fibronectin expression in mouse glomerular mesangial cells[J].European Journal of Pharmacology, 2010, 641(1):7-14.
[9] JUNG H A, ALI M Y, CHOI J S.Promising inhibitory effects of anthraquinones, naphthopyrone, and naphthalene glycosides, from Cassia obtusifolia on α-glucosidase and human protein tyrosine phosphatases 1B[J].Molecules, 2017, 22(1):28.
[10] NIE C H, ZHANG F G, MA X W, et al.Determination of quality markers of Xuezhiling tablet for hyperlipidemia treatment[J].Phytomedicine, 2018, 44:231-238.
[11] JUNG H A, ALI M Y, JUNG H J, et al.Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases[J].Journal of Ethnopharmacology, 2016, 191:152-160.
[12] XIE H H, GU Q L, CHEN W J, et al.Mitigation of oxidative stress and inflammatory factors, along with the antibrowning and antimicrobial effects of Cassia seed microbial fermentation solution[J].Frontiers in Microbiology, 2024, 15:1400505.
[13] XIE H H, HE S X, YU Z J, et al.Investigation on bowel regulation and constipation relief based on the microbial fermentation solution of Cassia seed[J].Journal of Ethnopharmacology, 2025, 342:119412.
[14] TIAN M Y, NIE L, YIN Y Q, et al.Study on quality analysis of different species of Coptidis rhizome based on fingerprint-effect relationship[J].Phytochemical Analysis, 2024, 35(1):77-86.
[15] LUO H Y, WU H W, WANG L X, et al.Hepatoprotective effects of Cassiae Semen on mice with non-alcoholic fatty liver disease based on gut microbiota[J].Communications Biology, 2021, 4:1357.
[16] WONG S M, WONG M M, SELIGMANN O, et al.New antihepatotoxic naphtho-pyrone glycosides from the seeds of Cassia tora[J].Planta Medica, 1989, 55(3):276-280.
[17] ROSSI M, AMARETTI A, LEONARDI A, et al.Potential impact of probiotic consumption on the bioactivity of dietary phytochemicals[J].Journal of Agricultural and Food Chemistry, 2013, 61(40):9551-9558.
[18] NOBILI V, PUTIGNANI L, MOSCA A, et al.Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease:Which strains act as health players?[J].Archives of Medical Science, 2018, 14(1):81-87.
[19] CHOI S E, HWANG Y, LEE S J, et al.Mitochondrial protease ClpP supplementation ameliorates diet-induced NASH in mice[J].Journal of Hepatology, 2022, 77(3):735-747.
[20] WIEËRS G, BELKHIR L, ENAUD R, et al.How probiotics affect the microbiota[J].Frontiers in Cellular and Infection Microbiology, 2020, 9:454.
[21] SONG W, WEN R X, LIU T Q, et al.Oat-based postbiotics ameliorate high-sucrose induced liver injury and colitis susceptibility by modulating fatty acids metabolism and gut microbiota[J].The Journal of Nutritional Biochemistry, 2024, 125:109553.
[22] ARELLANO-GARCÍA L I, PORTILLO M P, MARTÍNEZ J A, et al.Postbiotics for the management of obesity, insulin resistance/type 2 diabetes and NAFLD.Beyond microbial viability[J].Critical Reviews in Food Science and Nutrition, 2025,65(29):6209-6232.
[23] ARON-WISNEWSKY J, VIGLIOTTI C, WITJES J, et al.Gut microbiota and human NAFLD:Disentangling microbial signatures from metabolic disorders[J].Nature Reviews Gastroenterology & Hepatology, 2020, 17(5):279-297.
[24] HU W B, GAO W Y, LIU Z M, et al.Specific strains of Faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation[J].Nutrients, 2022, 14(14):2945.
[25] ZHU M Z, WANG X, WANG K, et al.Lingguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites[J].Frontiers in Cellular and Infection Microbiology, 2023, 13:1066053.
[26] ZHAI Q L, WU H Y, ZHENG S Y, et al.Association between gut microbiota and NAFLD/NASH:A bidirectional two-sample Mendelian randomization study[J].Frontiers in Cellular and Infection Microbiology, 2023, 13:1294826.
[27] SUN C R, XIONG X, LIU M Y, et al.Bacteroides ovatus alleviates high-fat and high-cholesterol-induced nonalcoholic fatty liver disease via gut-liver axis[J].Biomedicine & Pharmacotherapy, 2024, 178:117156.
[28] CHEN D L, WANG Y F, YANG J M, et al.Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites[J].Frontiers in Pharmacology, 2024, 15:1343755.
[29] YE J, ZHAO Y, CHEN X M, et al.Pu-erh tea ameliorates obesity and modulates gut microbiota in high fat diet fed mice[J].Food Research International, 2021, 144:110360.
[30] ZHUGE A X, LI B, YUAN Y, et al.Lactobacillus salivarius LI01 encapsulated in alginate-pectin microgels ameliorates D-galactosamine-induced acute liver injury in rats[J].Applied Microbiology and Biotechnology, 2020, 104(17):7437-7455.
[31] MARÍ M, DE GREGORIO E, DE DIOS C, et al.Mitochondrial glutathione:Recent insights and role in disease[J].Antioxidants, 2020, 9(10):909.
[32] YOSHINARI O, IGARASHI K.Anti-diabetic effect of pyroglutamic acid in type 2 diabetic Goto-Kakizaki rats and KK-Ay mice[J].British Journal of Nutrition, 2011, 106(7):995-1004.
[33] SUTHIPHASILP V, RUJANAPUN N, KUMBOONMA P, et al.Antidiabetic and cytotoxic activities of rotenoids and isoflavonoids isolated from Millettia pachycarpa Benth[J].ACS Omega, 2022, 7(28):24511-24521.
[34] FELLMAN J H, ROTH E S, AVEDOVECH N A, et al.The metabolism of taurine to isethionate[J].Archives of Biochemistry and Biophysics, 1980, 204(2):560-567.
[35] LI Y, ZHAO D Y, QIAN M Y, et al.Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota[J].British Journal of Pharmacology, 2022, 179(9):2054-2077.
[36] DOST A, STRAUGHAN J K, SORAHAN T.Cancer incidence and exposure to 4,4′-methylene-bis-ortho-chloroaniline (MbOCA)[J].Occupational Medicine, 2009, 59(6):402-405.
[37] JENNINGS E A, ABI-RACHED Z H, JONES D E, et al.3-Methylglutarylcarnitine:A biomarker of mitochondrial dysfunction[J].Clinica Chimica Acta, 2023, 551:117629.
[38] BATKE M, GÜTLEIN M, PARTOSCH F, et al. Innovative strategies to develop chemical categories using a combination of structural and toxicological properties[J].Frontiers in Pharmacology, 2016, 7:321.
Options
文章导航

/

〈 〉

技术支持：北京玛格泰克科技发展有限公司